

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 38949

**Title:** Advances in molecular, genetic and immune signatures of gastric cancer. Are we ready to apply them in our patients' decision making?

**Reviewer's code:** 00068723

**Reviewer's country:** Japan

**Science editor:** Li-Jun Cui

**Date sent for review:** 2018-03-28

**Date reviewed:** 2018-03-29

**Review time:** 15 Hours

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

## SPECIFIC COMMENTS TO AUTHORS

The authors reviewed current status of molecular therapy for gastric cancer. They provided information on genetic or molecular alteration of the cancer. As they concluded, there would be hurdled for the molecular therapies to be applied clinically.



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://** www.wjgnet.com

Readers would be informed of plenty of studies. Most of the manuscript was composed of introduction of experimental information or clinical trials. It would be better to speculate or refer literature for the reason of the limitation of clinical trials.

#### **INITIAL REVIEW OF THE MANUSCRIPT**

##### ***Google Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

##### ***BPG Search:***

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

## PEER-REVIEW REPORT

**Name of journal:** World Journal of Gastrointestinal Oncology

**Manuscript NO:** 38949

**Title:** Advances in molecular, genetic and immune signatures of gastric cancer. Are we ready to apply them in our patients' decision making?

**Reviewer's code:** 03728203

**Reviewer's country:** Poland

**Science editor:** Li-Jun Cui

**Date sent for review:** 2018-03-28

**Date reviewed:** 2018-04-03

**Review time:** 6 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input checked="" type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input checked="" type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input checked="" type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

### SPECIFIC COMMENTS TO AUTHORS

The paper provides a comprehensive review of molecular-based approach to the gastric cancer which, from the perspective of personalized oncology, is the most current and advanced. The authors presented the state of art concerning latest clinical trials and



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://** www.wjgnet.com

confronted them with the clinical practice and perspectives for future. The concept of paper is very accurate, as nowadays there is a multitude of molecular agents that are tried in therapy of gastric cancer and the issue needs to be summed up. I do not have any complaint about the organization of the paper, as the consecutive paragraphs are organized in a logical order. However, considering the definition and aim of reviews, such a paper should be clear, easy to read, concise and provide informative tables. The presented paper is too long and hard to read at once. In my opinion the Table 2 contains the clue of the paper but now it is prepared carelessly and it lacks some important information. From editorial point of view the paper makes very bad impression. The authors did not provide the required format that is clearly defined in the guidelines for authors. There is a wrong font and spacing, the title is too long, there are no ORCID numbers, there is no core tip, there is no information about financial support, there are some mistakes in references and the tables are in the wrong format. All of these suggest that the authors had rather careless attitude towards the guidelines. I wonder if such approach should be rewarded with the possibility of publication. The paper should be read by a native speaker. Suggestions to the authors: 1) To shorten the main text and present some of the content in reorganized Table 2. 2) To add additional columns in Table 2 – name of the targeted agent, name of the exact trials, phase of the trials, short characterization of the targeted population, if it was first/second line therapy, the final results, the conclusion from each study 3) To prepare the paper according to the guidelines for authors.

## INITIAL REVIEW OF THE MANUSCRIPT

### *Google Search:*

- ☐ The same title
- ☐ Duplicate publication



**Baishideng  
Publishing  
Group**

7901 Stoneridge Drive, Suite 501,  
Pleasanton, CA 94588, USA  
**Telephone:** +1-925-223-8242  
**Fax:** +1-925-223-8243  
**E-mail:** bpgoffice@wjgnet.com  
**https://** www.wjgnet.com

☐ Plagiarism

☐ No

***BPG Search:***

☐ The same title

☐ Duplicate publication

☐ Plagiarism

☐ No